Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 900964 | ISIN: US64125C1099 | Ticker-Symbol: NB3
Tradegate
04.06.25 | 12:53
110,75 Euro
+1,61 % +1,75
1-Jahres-Chart
NEUROCRINE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
NEUROCRINE BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
109,10110,2016:44
109,10110,2016:40

Aktuelle News zur NEUROCRINE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiGuggenheim maintains buy rating on Neurocrine Bio stock amid growth prospects3
MiGuggenheim behält Kaufempfehlung für Neurocrine Bio-Aktie aufgrund von Wachstumsaussichten bei2
DiNxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-111756879Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that its partner, Neurocrine Biosciences ("Neurocrine") has dosed the first...
► Artikel lesen
MoAnalyst Expectations For Neurocrine Biosciences' Future1
NEUROCRINE BIOSCIENCES Aktie jetzt für 0€ handeln
MoNeurocrine Biosciences Announces Phase 4 KINECT-PRO Data259WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX), Monday announced data from the Phase 4 KINECT-PRO open-label study, evaluating patient-reported outcomes on the use of INGREZZA capsules...
► Artikel lesen
28.05.Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 202593SAN DIEGO, May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia...
► Artikel lesen
27.05.Stifel hält an Kursziel von 166 US-Dollar für Neurocrine Bio-Aktien fest3
27.05.Stifel maintains $166 target on Neurocrine Bio shares1
23.05.Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $03
22.05.NEUROCRINE BIOSCIENCES INC - 8-K, Current Report2
21.05.NEUROCRINE BIOSCIENCES INC - S-8, Securities to be offered to employees in employee benefit plans18
16.05.Neurocrine Presents Encouraging New Data From Phase 4 Study Of Ingrezza In Tardive Dyskinesia355WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX) Friday announced new encouraging data from a Phase 4 study of Ingrezza in patients with tardive dyskinesia, a neurological disorder...
► Artikel lesen
16.05.Neurocrine berichtet über anhaltende Vorteile von CRENESSITY in CAH-Studie5
16.05.Neurocrine berichtet über verbesserte Lebensqualität in Studie zu Tardiver Dyskinesie6
16.05.Neurocrine reports lasting benefits of CRENESSITY in CAH study2
16.05.Neurocrine reports quality of life gains in tardive dyskinesia study2
16.05.Neurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying1
08.05.Neurocrine Reports Positive Data From Phase 3 CAHtalyst Pediatric Study Of CRENESSITY316WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX) Thursday announced positive results from the Phase 3 CAHtalyst Pediatric study of CRENESSITY in Congenital adrenal hyperplasia, a group...
► Artikel lesen
08.05.Neurocrine Biosciences, Inc.: Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst Pediatric Study Demonstrating CRENESSITY Reduces Glucocorticoid Dosing While Maintaining or Improving ...98- Data Consistent Across All Patient Subgroups, Including Demographic Subgroups, by Baseline Androstenedione Levels and by Baseline Glucocorticoid Dose - Findings...
► Artikel lesen
07.05.Neurocrine hands back 2 CNS gene therapy programs to Voyager2
Weiter >>
134 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1